Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummaryMay 01, 2017	Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster	View HTML Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes 11.8 KB
Toggle SummaryApr 26, 2017	Onconova Therapeutics Announces Closing of Public Offering of Common Stock NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the	View HTML Onconova Therapeutics Announces Closing of Public Offering of Common Stock 15.6 KB
Toggle SummaryApr 26, 2017	Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar, President & CEO, will present an overview at	View HTML Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC 15.6 KB
Toggle SummaryApr 21, 2017	Onconova Therapeutics Announces Pricing of Public Offering of Common Stock Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes	View HTML Onconova Therapeutics Announces Pricing of Public Offering of Common Stock 16.3 KB
Toggle SummaryApr 20, 2017	Onconova Therapeutics Announces Proposed Public Offering of Common Stock Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes	View HTML Onconova Therapeutics Announces Proposed Public Offering of Common Stock 15.2 KB
Toggle SummaryApr 04, 2017	Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association for Cancer Research (AACR) Annual Meeting	View HTML Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting 83.4 KB
Toggle SummaryMar 27, 2017	Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results NEWTOWN, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes, today provided a	View HTML Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results 36.3 KB
Toggle SummaryMar 21, 2017	Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences NEWTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at the Sachs Fifth	View HTML Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences 15.4 KB
Toggle SummaryMar 16, 2017	Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Monday, March 27, 2017	View HTML Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results 12.7 KB
Toggle SummaryMar 02, 2017	Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March NEWTOWN, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at: Maxim Inaugural	View HTML Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March 17.8 KB